Form 4: Catalyst Pharmaceuticals Director Exercises Stock Options

Director Donald A. Denkhaus exercised options to purchase 50,000 shares of Catalyst Pharmaceuticals common stock at $2.24 per share.

Summary

• On January 8, 2025, Donald A. Denkhaus, a director at Catalyst Pharmaceuticals, exercised options to purchase 50,000 shares of common stock.
• The exercise price was $2.24 per share.
• Following the transaction, Mr. Denkhaus directly owns 491,079 shares of common stock.
• He also holds options to purchase 162,274 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of a standard insider transaction. It does not indicate positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It provides transparency into the holdings of company directors.

Comparison to Industry Standards

• Stock option exercises are a standard form of compensation for directors and executives in publicly traded companies.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement.
• The exercise price of $2.24 is specific to the terms of the options granted to Mr. Denkhaus and is not directly comparable to other companies without knowing their specific option plans.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.

Key Dates

Keywords

stock options, insider trading, share ownership, Catalyst Pharmaceuticals, director, CPRX